Article Contents ::

Details About Generic Salt ::  Dextroam

Main Medicine Class:: CNS stimulant, Amphetamine   

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

 

Drugs Class ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Indications for Drugs ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Dose ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Contraindication ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Precautions ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Side Effects ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Mode of Action ::  

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Interactions ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

Drug Assesment ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Storage/Management ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Drug Notes ::

(DEX-troe-am-FET-uh-meen SULL-fate)
Dexedrine
Tablets
5 mg
Dexedrine Spansules
Capsules, sustained-release
5 mg
Capsules, sustained-release
10 mg
Capsules, sustained-release
15 mg
DextroStat
Tablets
5 mg
Class: CNS stimulant, Amphetamine

 

 Action Activates noradrenergic neurons causing CNS and respiratory stimulation; stimulates satiety center in brain causing appetite suppression.

 

 Indications Treatment of narcolepsy, attention-deficit disorder with hyperactivity; adjunct therapy for short-term (ie, few weeks) exogenous obesity when alternative therapy has been ineffective.

 

 Contraindications Advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reactions to sympathomimetic amines; glaucoma; agitated states; history of drug abuse; concurrent use or within 14 days of MAOI use.

 

 Route/Dosage

Narcolepsy

Adults (older than 12 yr): PO 10 mg/day; may increase weekly by 10 mg to max 60 mg/day in divided doses.

Children (6 to 12 yr): PO 5 mg/day; may increase weekly by 5 mg to max 60 mg/day in divided doses.

Attention Deficit Disorder

Children 6 yr or older: PO 5 mg/day; may increase weekly by 5 mg to max 40 mg/day in divided doses. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Children 3 to 5 yr: PO 2.5 mg/day; may increase weekly by 2.5 mg. Usual range is 0.1 to 0.5 mg/kg/dose q morning.

Exogenous Obesity

Adults 12 yr or older: PO 5 to 10 mg 30 to 60 min before meals, up to 30 mg/day. Long-acting form: 10 to 15 mg q morning.

 

 Interactions

Guanethidine Amphetamines may decrease effectiveness. MAOIs, furazolidone: Hypertensive crisis and intracranial hemorrhage may occur. Tricyclic antidepressants: May decrease amphetamine effect. Urinary Acidifiers (eg, Ammonium Chloride, Ascorbic Acid): May decrease amphetamine levels. Urinary Alkalinizers (eg, Acetazolamide, Sodium Bicarbonate): May increase amphetamine levels.

 

 Lab Test Interferences Plasma and urinary steroid levels may be altered.

 

 Adverse Reactions

CARDIOVASCULAR: Palpitations; tachycardia; hypertension; arrhythmias. CNS: Nervousness; tremors; dizziness; insomnia, euphoria; headache. DERMATOLOGIC: Urticaria. EENT: Dry mouth; unpleasant taste. GI: Diarrhea; constipation; anorexia. GU: Impotence.

 

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Do not use as anorectic agent in children younger than 12 yr. Not recommended for attention-deficit disorder in children younger than 3 yr. Drug Dependence: Amphetamines have been extensively abused. Tartrazine Sensitivity: Some products contain tartrazine, which may cause allergic reactions in susceptible individuals. Tolerance: May occur; do not exceed recommended dose to overcome this.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Limit patient’s access to medication.
  • Give medication 30 to 45 min before meals. Give sustained-release tablets once daily in morning.
  • Do not crush or open sustained-release tablets.

 

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Assess baseline nutritional status.
  • Document any abnormal behavior.
  • Document monthly measurement of physical growth in children.
  • Document weight weekly.
  • Notify health care provider and withhold medication if BP increases by 20 mm Hg or if heart arrhythmias or increase in heart rate develops.
OVERDOSAGE: SIGNS & SYMPTOMS
  Restlessness, tremor, hyperreflexia, confusion, hallucinations, panic, fatigue, depression, convulsions, coma, arrhythmias, hypertension, hypotension, circulatory collapse, nausea, vomiting, diarrhea, abdominal cramps

 

 Patient/Family Education

  • Instruct patient to take medication early in morning and, if possible, to take last dose at bedtime.
  • Tell patient to record body weight weekly.
  • Instruct patient/family to measure height monthly if patient is child.
  • Tell patient to limit intake of coffee, tea, cocoa, chocolate, and caffeinated soft drinks.
  • Explain importance of good oral hygiene to prevent or treat dry mouth and changes in breath odor.
  • Instruct patient to be aware of increased agitation, palpitations, and dizziness, and to take precautions while performing tasks that require physical coordination or mental alertness.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.